• Policy
• Will Dukarb Plus next month rise as Boryung’s savior?
• by Lee, Tak-Sun May 30, 2022 05:42am

• Policy
• Chong Kun Dang faces Hanmi due to Rivaroxaban 2.5mg
• by Lee, Tak-Sun May 29, 2022 05:14pm

• Policy
• Xarelto's generic 15 items have been revoked
• by Lee, Hye-Kyung May 25, 2022 05:47am

• Policy
• GSK meningococcal vaccine Bexero PFS was approved in Korea
• by Lee, Hye-Kyung May 25, 2022 05:47am

• Policy
• Atopic Dupixent Pen will be available in Korea
• by Lee, Hye-Kyung May 24, 2022 05:54am

• Policy
• Fexclu priced at 90% of the weighted average of K-CAB+PPIs
• by Lee, Tak-Sun May 20, 2022 06:12am

• Policy
• The MFDS will gradually disclose the results of GMP survey
• by Lee, Hye-Kyung May 20, 2022 06:11am

• Policy
• Green light to Sprycel's reimb with indication expansion
• by Lee, Tak-Sun May 20, 2022 06:11am

• Policy
• HIRA plans to improve the overall management system
• by Lee, Tak-Sun May 20, 2022 06:11am

• Policy
• 34 new global drugs, including Beleodaq, are urgently needed
• by Lee, Tak-Sun May 18, 2022 05:52am